Intriguingly, despite the lack of a molecular pathway characterization, a recent study demonstrated the promising potential efficacy of two approved epidermal growth factor receptor (EGFR) inhibitors for FA-related head and neck squamous cell carcinoma [140]. Here, EGFR is linked to Friedreich ataxia.